Sangamo Therapeutics, Inc. announced that the European Society of Gene & Cell Therapy (ESGCT) has accepted six Sangamo abstracts for presentation at the 30th Annual Congress being held October 24-27, 2023, in-person in Brussels, Belgium. Presentations will focus on the progression of Sangamo's pre-clinical programs, including data from its neurology epigenetic regulation programs, and advancements in the CAR-Treg pipeline. Data to be presented at the ESGCT Annual Congress include an oral presentation demonstrating how zinc finger Activators (ZF-As) may be designed to potentially address neurodevelopmental disorders such as autism spectrum disorder and intellectual disability, for which limited therapeutic treatments currently exist.

This presentation will show how ZF-As can be designed to restore normal gene and protein expression of SCN2A in vitro and in vivo. This will be accompanied by a poster presentation demonstrating Shank3 gene activation, mediated by ZF-As as a potential therapeutic approach for Phelan-McDermid syndrome. Both datasets originate from pre-clinical programs previously co-developed in partnership with Novartis.

Additional presentations at the ESGCT annual Congress will unveil for the first time pre-clinical data showing that autologous MOG-CAR-Tregs may provide a long-lasting treatment option to potentially address the underlying cause of multiple sclerosis, as well as updated pre-clinical data evaluating IL23R-CAR-Tregs as a potentially effective treatment option to address inflammation for patients with Crohn's disease. Data will also showcase platform capability of efficient and durable epigenetic cell engineering using compact ZF-Repressors to target immune checkpoints with the potential to improve the anti-tumor activity of T cells in cancer therapy. ESGCT Annual Congress Presentations and Invited Sessions Epigenetic Regulation for Neurology: Zinc Finger Activators restore normal gene and protein expression in a mouse model of SCN2A haploinsufficiency; Abstract No.

OR09; Oral Presentation - October 24; 17:00-19:00; Shank3 Gene Activation Mediated by Zinc Finger Activators (ZF- As) as a Therapeutic Approach for Phelan- McDermid Syndrome; Abstract No. P415; Poster Presentation - October 25; 17:00 to 18:15 and October 26; 20:30 to 21:30; Cell Therapy Regulatory T-Cells (CAR-Tregs); Myelin Oligodendrocyte Glycoprotein (MOG)-CAR-Tregs - A novel approach to treat multiple sclerosis; Abstract No. P475; Poster Presentation - October25; To learn more, visit and connect with the company on LinkedIn and Twitter.